Molecular Diagnostics for Cancer Drug Development
The must attend event for oncologists
This is the must-attend forum for cancer and diagnostic professionals trying to navigate the biomarker-driven oncology drug development space. Designed with the community in mind, the summit will address the core challenges in incorporating molecular and companion diagnostics into oncology drug development. Right from basic biomarker identification and assay validation, to clinical development and commercialization. View the agenda pages here or download the brochure.
We’ve worked with the key figures of the MDx in oncology world from Pfizer, Johnson & Johnson, Novartis, GSK, AstraZeneca,Bristol-Myers Squibb, Merck, FDA, NCI, Genentech, Amgen, Biogen Idec, Asuragen, Almac, Expression Pathology and so many others, and this is the result. Click here to view the full speaker line-up.
What’s on the agenda?
The Molecular Diagnostics for Cancer Drug Development meeting is the perfect place to meet drug industry leaders and pioneering researchers to learn the latest approaches for stratifying patient populations with molecular diagnostics and how to increase your oncology drug program’s chance of success. Here are just some of the topics our experts will be addressing:
Where are we now with the development, approval and commercialization of companion diagnostics in oncology? What are the different patient stratification strategies companies are taking, both in large pharma and smaller drug developing companies?
What are the latest tools, technologies and integrated approaches to improve biomarker discovery and how can we predict patient response to oncology drug combinations?
How do you successfully translate treatment stratification markers from bench to bedside and move from a research grade assay towards a clinically useful diagnostic test?
How do you take a biomarker test from clinical validation to commercialization?
What are the sample requirements for IVD/MDx development, how do you acquire your own clinical trial specimens for biomarker identification and when do you use biobanks versus clinical trial samples?
What’s the latest FDA guidance and regulation for CDx development and approval?
View full agenda
Why attend?
Every presentation and contact will help you improve your research and business aims – everyone at the meeting is here to discuss how to predict response to oncology therapeutics and how to stratify patient populations for increased drug success.
Don’t just listen to speakers and attendees – meet them and discuss your work in our intimate and informal conference setting. Plus, we’ll make sure you meet everybody you want to in our dedicated speed networking session.
Receive tailored guidance on achieving patient stratification – our pre-conference workshops are a fantastic opportunity to get the information and contacts you need to achieve your research and business aims (over and above the inside information you will gain from the meeting itself).
Who’s this meeting for?
Whether you are new to the field or expanding your existing capabilities around biomarker development and companion diagnostics, this meeting is a one-stop shop of the latest developments and strategies you need to be aware of. That means anyone involved with: Oncology, Biomarkers, (Companion) diagnostics, Molecular profiling, Translational medicine, Personalized medicine, Pharmacogenomics/pharmacogenetics, Pathology
http://moleculardiagnostics-cancer.com